ERBB2 and breast cancer: Here in a single neoadjuvant chemotherapy treated breast cancer cohort we evaluate the prognostic value (Overall survival (OS) and Disease-free survival (DFS)) of all major immunocyte cell ratios (NLR, LMR, NWR, LWR, MWR and PLR) by major breast cancer subtypes (Luminal A, Luminal B, Her2 positive and Triple negative/Basal).